Skip to main content
Premium Trial:

Request an Annual Quote

Jeffrey Jeddeloh, Stephen Macevicz, Christine Peponnet

Jeffrey Jeddeloh, Stephen Macevicz, and Christine Peponnet have joined the new US subsidiary of French DNA synthesis firm DNA Script.  

Jeddeloh was appointed as vice president of business development and commercial strategy. Most recently, he was director of business development for Roche Molecular Solutions. Prior to that, he was R&D director at Orion Genomics. He holds a PhD from Washington University and an MBA from the University of Wisconsin.

Macevicz has become the firm's vice president of intellectual property. Previously, he was vice president of IP at Sequenta and at Ion Torrent, as well as senior IP attorney at Becton Dickinson. He holds a PhD in biophysics and a JD from the University of California, Berkeley.

Peponnet has joined the company as vice president of technology development. Most recently, she was head of the biosystems group at CEA (Center for Atomic Energy), where she helped to develop a microfluidic technology that was licensed to Advanced Liquid Logic, which was later acquired by Illumina. Prior to that, she worked at Caliper Technologies, and before that, she was head of genotyping R&D at Genset.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.